LLY vs MS: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
VS
Morgan Stanley · Financial Services
$189.30
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
MS has more upside to fair value
(+45.0%).
MS trades at a lower forward P/E
(16.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
MS |
| Current Price |
$934.34 |
$189.30 |
| Fair Value Estimate |
$1,098.43 |
$274.49 |
| Upside to Fair Value |
+17.6%
|
+45.0%
|
| Market Cap |
$882.8B |
$300.6B |
| Forward P/E |
33.1x
|
16.4x
|
| EV / EBITDA |
27.9x
|
24.4x
|
| Price / Sales |
12.2x
|
2.5x
|
| Price / FCF |
65.0x
|
-16.8x
|
| Revenue Growth YoY |
+55.5%
|
+18.8%
|
| Gross Margin |
82.7%
|
58.0%
|
| Operating Margin |
46.3%
|
19.5%
|
| Return on Equity |
101.3%
|
16.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Accumulation Zones
| Metric |
LLY |
MS |
| Zone Low |
$823.82 |
$205.87 |
| Zone High |
$933.67 |
$233.32 |
| In Buy Zone? |
No
|
Yes
|